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iETTER TO THE EDITOR
mproving  gentamicin  dosing:  A  suggested
pproach  to  a  simpliﬁed  once-daily  dosing
chedule
o the  Editor,
Traditionally,  gentamicin  has  been  administered
t a  dosage  of  3—5  mg/kg  daily  in  divided  doses,
ypically every  8  h.  However,  therapeutic  drug  mon-
toring has  shown  that  multiple  daily  dosing  rarely
chieves  adequate  peaks  and  often  produces  high
rough levels  [1].  During  the  last  two  decades,
here has  been  a  move  toward  single  daily  dos-
ng. Randomized  controlled  trials  have  indicated
hat once-daily  aminoglycoside  administration  is
s efﬁcacious  as  the  traditional  multiple-dose
ethod; may  lower,  but  not  eliminate,  the  risk  of
rug-induced  nephrotoxicity  and  ototoxicity;  and
s simpler,  less  time-consuming  and  more  cost-
ffective  than  multiple-dose  regimens  [2—4]. The
ims of  once-daily  dosing  are  as  follows:  (1)  to
chieve  high  peak  serum  levels  [10  times  the  min-
mum inhibitory  concentration  (MIC)]  for  maximum
acterial  kill,  as  efﬁcacy  relates  to  the  ratio  by
hich  post-dose  levels  exceed  MIC;  and  (2)  to
chieve a  short  period  of  low  drug  concentration
o minimize  toxicity  (approximately  4 h).
Data  from  Table  1  clearly  show  that  most  patients
reated with  gentamicin  at  our  institution  over  a
eriod of  six  months  were  given  multiple  daily
oses, and  97.3%  (72/74)  of  gentamicin  prescrip-
ions were  for  less  than  5  mg/kg.  When  the  single
mall dose  prescriptions,  which  were  most  likely
iven  for  prophylaxis,  were  excluded,  multiple
aily dosing  was  found  to  account  for  89.2%  (74/83)
f the  prescriptions  compared  to  10.8%  (9/83)
or the  once-daily  dosing.  When  the  once-daily
osing regimen  was  used,  only  one  patient  (1/9)
eceived  an  optimal  dose  of  5 mg/kg.  In  contrast,
5.7% (19/74)  of  the  patients  treated  with  multiple
ivided  doses  were  given  suboptimal  doses  of  less
han 3  mg/kg.  Most  prescriptions  (89%)  were  given
y surgeons  and  gynecologists,  suggesting  that  this
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y internal  medicine  physicians.
Aminoglycosides  show  concentration-dependent
ctivity.  The  duration  of  the  post-antibiotic  effect
PAE) of  aminoglycosides  increases  with  their  peak
oncentration.  Once-daily  dosing  results  in  a  high
eak serum  concentration  (10  times  the  MIC),  and
he serum  concentration  can  fall  below  the  MIC
or a  short  period  before  the  next  dose  without
oss of efﬁcacy.  Moreover,  a  high  peak  serum  level
educes  concern  about  the  adaptive  resistance  phe-
omenon,  which  may  arise  due  to  the  emergence  of
 resistant  subpopulation  or  the  downregulation  of
minoglycoside  uptake  following  the  initial  expo-
ure of  the  organism  to  the  drug  (known  as  the  ﬁrst
xposure  effect)  [5]. In  cases  with  renal  impair-
ent, extension  of  the  dosage  intervals  is  favored
ver the  reduction  of  the  dose  with  once-daily
dministration,  because  extended  dosage  intervals
chieve  higher  peak  levels  with  enhanced  bacteri-
idal activity.  Until  further  evidence  is  available,
nce-daily  dosing  should  not  be  used  in  the  follow-
ng groups  of  patients:  (1)  those  with  severe  renal
mpairment,  i.e.,  CrCI  <  20  mL/min  and/or  patients
n dialysis;  (2)  those  with  infective  endocarditis;
3) those  with  ascites;  (4)  those  with  major  burns
>20%); (5)  those  with  exacerbated  cystic  ﬁbrosis;
nd (6)  pregnant  patients.
The  recommended  once-daily  gentamicin  dose
s 5—7  mg/kg  per  day.  A  higher  dose  has  a clear
dvantage in  patients  with  an  increased  volume  of
rug distribution,  e.g.,  those  with  congestive  heart
ailure or ‘‘leaky’’  capillaries  as  a  result  of  bac-
eremia.  No  controlled  studies  have  compared  5
ersus 7  mg/kg  of  gentamicin,  but  clinical  experi-
nce with  the  7  mg/kg  dosage  is  substantial  [6].  The
Hartford Hospital  Nomogram’  uses  a constant  dose
f gentamicin  of  7  mg/kg  for  all  eligible  patients
6]. A  gentamicin  level  measured  anytime  between
 and  14  h  after  the  start  of  the  ﬁrst  gentamicin
nfusion is used  to  establish  the  dosing  interval  from
he nomogram.  For  example,  if  the  serum  level  falls
n the  area  designated  q24hr,  q36hr  or  q48hr  in  the
omogram,  the  new  dosing  interval  becomes  every
nces. Published by Elsevier Ltd. All rights reserved.
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Table  1  Gentamicin  dosing  in  adults  at  Qatif  Central  Hospital  over  a  period  of  six  months  (January—June,  2012).a
Dose  cohortb No.  of  patients  Daily  dose  (mg/kg)c Service  Durationd Agee
<3  3—4  ≥5  Medicine  Surgery  OB/GYN
SD  8  8  —  —  —  6  2  —  43  (23—75)
OD  9  6  2  1  4  4  1  7  (3—7)  57  (19—91)
MD  74  19  53  2  6  39  29  5  (1—14)  34  (16—67)
Total  91  33  55  3  10  49  32
a Exclusions include the following patients/conditions: pediatric patients, renal impairment, burns, endocarditis, pregnancy,
cystic ﬁbrosis and patients with ascites.
b SD, single dose; OD, once-daily regimen; MD, multiple-dose regimen.
c Doses were calculated based on ideal body weight but the actual body weight was used if it was less than the ideal body
weight.
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[d Values are modes (ranges).
e Values are means (ranges).
24  h,  36  h  or  48  h,  respectively;  however,  the  initial
dose remains  the  same.  Similarly,  if  a  once-daily
dose of  5 mg/kg  is  used,  the  ‘Urban-Craig  Nomo-
gram’ can  be  applied  to  monitor  and  interpret  the
gentamicin  levels  [5].  In  contrast  to  the  Hartford
nomogram, there  is  the  option  to  decrease  the  dos-
ing interval  to  every  12  h  for  patients  with  unusually
low drug  levels  after  dosage.  Alternatively,  pre-
dose levels  can  be  monitored  to  target  a  serum  level
of less  than  1  mg/L  before  the  administration  of the
next dose.
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